Member Info for dan1nat1

So are you currently in or out Donald?

Price of tin at an all time high according to a Sky News headline, should help with the numbers.

With breast cancer being very high profile this could be a great move with regards to attracting more grants. The university of Helsinki has already received a $5.2m grant from the US DoD -
https://www.helsinki.fi/fi/uutiset/terveempi-maailma/syopageenista-syovan-surma-jattirahoitus-helsingin-yliopistolle-uusien-laakehoitojen-kehittamiseksi-rintasyovan-hoitoon?utm_medium=social_owned&utm_source=twitter

This line is interesting and you have to wonder if Bex could be involved -
"We are also investigating whether MYC-based therapies can be combined with new immunotherapy therapies, says Juha Klefström , FICAN Research Professor and Research Director at the University of Helsinki."

We seem to be busier than normal in presentations / events / seminars at the moment. Tom on Twitter has brought a couple of new events to my attention -
https://macrophage-directed-therapies.com/speaker/juho-jalkanen/

https://macrophage-directed-therapies.com/speaker/maija-hollmen/

https://www.g20innovationleague.com/

Oil, SSV may have been a poor phrase to use, but in terms of company development what do you think hasn’t happened that should have done?

Placing or partner either is dilution by another name, and unless we get an more grants this is the way it will be until we get either Traumakine or Bex to market.

I’d put money on the fact Gaz doesn’t even watch the presentations, let alone get involved asking any questions.

Post all the negative comments you want, but at least back them up with a little more than your whiney why was Markku not correct that the shares price would allow me to sell out at the profit I’m happy with in the time scale he predicted rubbish.

You may not consider the advancement of Bex as shareholder value, you probably don’t even know Traumakine is currently in a P2/3 trial with initial readouts possibly in December. I along with many others do think this is shareholder value.

When the webinar was announced it was stated "to discuss updated MATINS data", maybe FARN had seen it as a way to give investors the same info as presented at the ESMO and give us the opportunity to ask questions relating to that and not as a general Q&A session?

P.35 of the latest corporate presentation, under Traumakine -

" Organ protection data release with the DoD"

We know this study is ongoing, but is this the first time they have talked about releasing the data?

Sorry Gaz I didn't realize you wanted an actual answer...you normally just want an unopposed rant.

You do still seem to be mixing up SSV with SP, until you get over the fact that nobody including Markku can tell you when the market will see fit to let the SP hit a certain price you are going to be disappointed. Value has been added its just not been recognized by the markets yet.

"what research can be done" well for a start you might look into when we might be getting our next updates, you were moaning about no news last Tuesday when anybody that had done the most basic research knew we had an update due on Friday.
"Research is fruitless" ...seriously?
"I take the results with a pinch of salt" you take the results of a scientific study with a pinch of salt?
"the market will let me know how good they are" you give the market to much credit

The point that got my attention was the very last sentence on the strategy slide: ”Build several partnerships with world leading pharma companies”

Heikkinen, that point also got my attention, you have to wonder if this is related to Markku's upcoming visit to the States?

I though you were selling up before last Friday Gaz? I notice you had nothing to say after Thursday and Fridays presentations when the SP was heading upward, now after a couple of down days you are back on banging your same unresearched comments about SSV.
Maybe its time you stop clinging onto that comment and do some research? Then you can decide for yourself if we are likely to see any SSV.

Did I hear Markku correctly, does he think we will be able to identify responders pre treatment before the end of the year?

If that is what he said this is massive!

“So its from that afterwards selected data you/we can calculate the probabilities. What if all 10 are taken into account, the result is even worse.”

Not really Donald, we are not going forward saying we have a new drug that can treat these 10 cancer types, so how on earth are you thinking the we have to put the other 5 in the chances of successful treatment?

You really don’t like Markku do you? And you really are starting to make yourself look a bit of a fool!

How do we get to a sensible offer without first further proving up what we have?

If Markku was to value us at £2-£5 billion as suggested by the deals he referred to last week, we would be currently priced at £40 - £100 per share! Clearly we need more results to get anywhere near that price, I’m willing to wait a while longer yet and it’s seems Markku is to.

No deal does not suggest there is a problem with the data, not matter how many times you try to imply it does!

If you took your vendetta against Markku off the table maybe you could see no deal might just mean Bex is progressing as planned and the longer Faron are in full control the better.

"All this feigned enthusiasm is a sign that licensing went wrong in the summer" with whom did we try to get a licensing deal in the summer? Can you not accept that the results for Bex have been positive and the longer we keep full control the better?
"and now we have to get funding from investors" we are not at market yet, one way or the other we were always going to have to get funding.
"Big pharmaceutical companies are not convinced of the existing data" have you taken a poll from those who viewed the ESMO presentation, or is this based on your own negative view?
"Markku is trying to convince small investors by talking up the share price." Clutching at straws now to suggest small investors can keep the lights on.
"Yesterday’s speeches are by no means in line with today’s news" what did you feel was missing from todays news?

How much did you lose on the Vap deal...

Have you factored in the survival rates of alternative immunotherapy options...which not not very high.

Also we are currently last line, what happens when we are testing on patients that have not already been through 2, 3 or 4 rounds of other treatments first?

Finally what happens when we can identify through bio markers the DCR group?

Markku mentioned the two deals in your link at last nights presentation, if he thinks we can achieve the same sort of valuations we are looking at a 10-20 bag from here...assuming no dilution!

Could we get that sort of valuation from one tie up or would we be looking at multiple licensing deals? I don't think currently we would get anywhere near that on a straight take over, which is why I am happy to wait for us further prove up what we have and potentially surpass those other deals.

Does anyone have a link for the ESMO presentation?

Has made his first appearance of the day paying 455.